CTLA4 blockade in mesothelioma: finally a competing strategy over cytotoxic/target therapy?
出版年份 2014 全文链接
标题
CTLA4 blockade in mesothelioma: finally a competing strategy over cytotoxic/target therapy?
作者
关键词
Mesothelioma, Anti-CTLA4 mAb, Tremelimumab, Immunotherapy, NIBIT-2013
出版物
CANCER IMMUNOLOGY IMMUNOTHERAPY
Volume 64, Issue 1, Pages 105-112
出版商
Springer Nature
发表日期
2014-09-19
DOI
10.1007/s00262-014-1609-9
参考文献
相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。- Association of PD-1, PD-1 Ligands, and Other Features of the Tumor Immune Microenvironment with Response to Anti-PD-1 Therapy
- (2014) J. M. Taube et al. CLINICAL CANCER RESEARCH
- Biomarkers for immune checkpoint inhibitors – Authors' reply
- (2014) Luana Calabrò et al. LANCET ONCOLOGY
- Epigenetic drugs as immunomodulators for combination therapies in solid tumors
- (2014) Luca Sigalotti et al. PHARMACOLOGY & THERAPEUTICS
- Immune checkpoint blockade in malignant mesothelioma
- (2014) Luana Calabrò et al. OncoImmunology
- Long-term survival and immunological parameters in metastatic melanoma patients who responded to ipilimumab 10 mg/kg within an expanded access programme
- (2013) Anna Maria Di Giacomo et al. CANCER IMMUNOLOGY IMMUNOTHERAPY
- Immunotherapy and the concept of a clinical cure
- (2013) Alexander M.M. Eggermont et al. EUROPEAN JOURNAL OF CANCER
- Phase III Randomized Clinical Trial Comparing Tremelimumab With Standard-of-Care Chemotherapy in Patients With Advanced Melanoma
- (2013) Antoni Ribas et al. JOURNAL OF CLINICAL ONCOLOGY
- Tremelimumab for patients with chemotherapy-resistant advanced malignant mesothelioma: an open-label, single-arm, phase 2 trial
- (2013) Luana Calabrò et al. LANCET ONCOLOGY
- Thalidomide versus active supportive care for maintenance in patients with malignant mesothelioma after first-line chemotherapy (NVALT 5): an open-label, multicentre, randomised phase 3 study
- (2013) Wieneke A Buikhuisen et al. LANCET ONCOLOGY
- New checkpoint inhibitors ride the immunotherapy tsunami
- (2013) Asher Mullard NATURE REVIEWS DRUG DISCOVERY
- Nivolumab plus Ipilimumab in Advanced Melanoma
- (2013) Jedd D. Wolchok et al. NEW ENGLAND JOURNAL OF MEDICINE
- Major Cancer Regressions in Mesothelioma After Treatment with an Anti-Mesothelin Immunotoxin and Immune Suppression
- (2013) R. Hassan et al. Science Translational Medicine
- Surgery in the treatment of malignant pleural mesothelioma: recruitment into trials should be the default position
- (2013) Avijit Datta et al. THORAX
- Anti-angiogenic therapies for malignant pleural mesothelioma
- (2012) Giovanni Luca Ceresoli et al. EXPERT OPINION ON INVESTIGATIONAL DRUGS
- Ipilimumab in Combination With Paclitaxel and Carboplatin As First-Line Treatment in Stage IIIB/IV Non–Small-Cell Lung Cancer: Results From a Randomized, Double-Blind, Multicenter Phase II Study
- (2012) Thomas J. Lynch et al. JOURNAL OF CLINICAL ONCOLOGY
- Multicenter, Double-Blind, Placebo-Controlled, Randomized Phase II Trial of Gemcitabine/Cisplatin Plus Bevacizumab or Placebo in Patients With Malignant Mesothelioma
- (2012) Hedy L. Kindler et al. JOURNAL OF CLINICAL ONCOLOGY
- Safety, Activity, and Immune Correlates of Anti–PD-1 Antibody in Cancer
- (2012) Suzanne L. Topalian et al. NEW ENGLAND JOURNAL OF MEDICINE
- Global mesothelioma deaths reported to the World Health Organization between 1994 and 2008
- (2011) Vanya Delgermaa et al. BULLETIN OF THE WORLD HEALTH ORGANIZATION
- Immune responses and immunotherapeutic interventions in malignant pleural mesothelioma
- (2011) Adam J. Bograd et al. CANCER IMMUNOLOGY IMMUNOTHERAPY
- Asbestos Induces Reduction of Tumor Immunity
- (2011) Naoko Kumagai-Takei et al. Clinical & Developmental Immunology
- VANTAGE 014: Vorinostat (V) in Patients With Advanced Malignant Pleural Mesothelioma (MPM) who Have Failed Prior Pemetrexed and Either Cisplatin or Carboplatin Therapy: A Phase III, Randomized, Double-Blind, Placebo-Controlled Trial
- (2011) L.M. Krug et al. EUROPEAN JOURNAL OF CANCER
- BRCA1 is an essential mediator of vinorelbine-induced apoptosis in mesothelioma
- (2011) Sara Busacca et al. JOURNAL OF PATHOLOGY
- Retreatment with pemetrexed-based chemotherapy in patients with malignant pleural mesothelioma
- (2011) Giovanni L. Ceresoli et al. LUNG CANCER
- Second-line chemotherapy in malignant pleural mesothelioma: Results of a retrospective multicenter survey
- (2011) P.A. Zucali et al. LUNG CANCER
- Dysregulation of the immune system caused by silica and asbestos
- (2010) Megumi Maeda et al. Journal of Immunotoxicology
- Pemetrexed Plus Cisplatin or Pemetrexed Plus Carboplatin for Chemonaïve Patients with Malignant Pleural Mesothelioma: Results of the International Expanded Access Program
- (2010) Armando Santoro et al. Journal of Thoracic Oncology
- Clinical Studies With Anti–CTLA-4 Antibodies in Non-melanoma Indications
- (2010) Luana Calabrò et al. SEMINARS IN ONCOLOGY
- Second-line treatment for malignant pleural mesothelioma
- (2009) Giovanni Luca Ceresoli et al. CANCER TREATMENT REVIEWS
- Guidelines for the Evaluation of Immune Therapy Activity in Solid Tumors: Immune-Related Response Criteria
- (2009) J. D. Wolchok et al. CLINICAL CANCER RESEARCH
- Phase III Trial of Pemetrexed Plus Best Supportive Care Compared With Best Supportive Care in Previously Treated Patients With Advanced Malignant Pleural Mesothelioma
- (2008) Jacek Jassem et al. JOURNAL OF CLINICAL ONCOLOGY
Publish scientific posters with Peeref
Peeref publishes scientific posters from all research disciplines. Our Diamond Open Access policy means free access to content and no publication fees for authors.
Learn MoreCreate your own webinar
Interested in hosting your own webinar? Check the schedule and propose your idea to the Peeref Content Team.
Create Now